



# Emerging biotech and biopharma clinical research in Japan and Asia-Pacific

Emerging biotech and biopharma clinical research is on the rise in Asia-Pacific

Emerging biotech and biopharma set up clinical trial sites are increasing fastest in Asia-Pacific<sup>1</sup>




54% of the world's urban population<sup>2</sup>

Japan and Asia-Pacific is the world's most populated region

As wealth in Asia increases, the region is becoming important as a medicines market

Middle-class consumption<sup>3</sup>



Regulatory efficiencies and timelines are improving rapidly across the region

JAPAC presents high quality clinical trials typically delivered with strong cost efficiencies



Meeting the regional and global aspirations of emerging biotech and biopharma

The advantages of Japan and Asia-Pacific as an emerging biotech and biopharma clinical trials destination are increasingly clear.

However, the region also presents regulatory complexities and several language and cultural variances that drive the need for specialized clinical research organisation support.

IQVIA Biotech in JAPAC provides comprehensive, flexible and fit-for-purpose clinical and commercial solutions specifically designed to meet the regional and global aspirations of dynamic and fast-moving emerging biotech and biopharma companies.



For more information contact: [Asiasales@iqvia.com](mailto:Asiasales@iqvia.com)

REFERENCES:

1. Frost & Sullivan. Asia: Preferred Destination for Clinical Trials (2020)
2. United Nations. 2018 Revision of World Urbanization Prospects. Last accessed May 2020, at <https://www.un.org/development/desa/publications/2018-revision-of-world-urbanization-prospects.html>
3. OECD Development Centre. The Emerging Middle Class in Developing Countries (2017). Last accessed May 2020, at <https://www.oecd.org/dev/44457738.pdf>